A novel approach for an automated liquid/liquid extraction system—principle and application for the determination of several trace contaminants in highly alloyed steels and base alloys
AbstractA novel automated liquid/liquid extraction system was developed for the determination of trace contaminants in unalloyed, alloyed and highly alloyed steels and super alloys. In the presented batch extraction system the aqueous phase and the non-water miscible organic phase were brought into close phase contact by high-speed stirring with a magnetic stir bar. Iodide complexes of Ag, Bi, Cd, Pb, Sb, Sn, Tl, and Zn were extracted from aqueous steel digests into 4-methylpentan-2-one (MIBK) containing 20 g L−1 trioctylphosphine oxide. Ag, Bi, Cd, Pb, and Tl were extracted quantitatively whereas the extraction yields of Sb, Sn, and Zn were 83%, 61% and 75% respectively. Using high resolution continuum source flame AAS (HR-CS-FAAS) for analyte quantification the method was validated using 21 certified steel reference materials (CRMs).
 Figure 
Capabilities of femtosecond laser ablation ICP-MS for the major, minor, and trace element analysis of high alloyed steels and super alloys
AbstractFemtosecond laser ablation inductively coupled plasma mass spectrometry was used for the quantification of 23 metallurgical relevant elements in unalloyed, alloyed and highly alloyed steels, and super alloys. It was shown that by using scanning mode ablation with large ablation spot diameters (250 μm), stable and representative sampling can be achieved for the majority of elements, except for bismuth and lead. For Bi and Pb up to 46%, temporal relative standard deviation (TRSD) was encountered, whereas for most other elements, the TRSDs were below 10%. Calibration with matrix-matched and non-matrix-matched standards provided similar agreement within the uncertainty of the certified values. However, the non-matrix-matched standard-based quantification was more influenced by interferences rather than ablation- or excitation-related matrix effects. The method was validated using 34 certified reference materials. 52Cr, 51V, or 55Mn were used as internal standards due to the fact that the Fe concentration was not certified for the majority of reference materials. The determined concentrations for major and minor elements indicate that the total matrix internal standardization (100 wt.%) is applicable, which requires no knowledge about the steel samples prior to analysis.
 FigureCRM chips embedded in epoxy resin
Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro
Microtubulin binding agents such as docetaxel have significant preclinical and clinical activity in the treatment of hormone-refractory prostate cancer. We have previously used median-effect analysis in vitro to define both synergistic and antagonistic drug combinations which may be of value in management of human disease. These studies extend our findings in defined prostate cancer cell lines. A semi-automated microtiter culture system was used. Docetaxel was combined with 18 other agents, incubated with DU 145, LnCaP or PC 3 prostate cancer cell lines for 72 h and the cells then incubated with MTT to determine cytotoxic effect. Both doublet and triplet combinations were examined. Synergy and antagonism as measured by the combination index were determined for each combination. The non-mutually exclusive criterion was applied. Docetaxel demonstrated cytotoxic additive effects or synergy with cis-retinoic acid, cyclosporin A and vinorelbine in all three cell lines. Docetaxel combined with either epirubicin or doxorubicin displayed cytotoxic synergistic effects in hormone-refractory DU 145 and PC 3 cell lines. In contrast, drugs which have been combined clinically to treat hormone-refractory prostate cancer, i.e. cisplatin, carboplatin or etoposide, were antagonistic when combined with docetaxel. We conclude that combinations of docetaxel with either cis-retinoic acid or vinorelbine may offer an enhanced cytotoxic effect in the management of hormone-refractory prostate cancer and need to be evaluated for therapeutic effect. The combination of docetaxel with an anthracycline was also synergistic in the two hormone-refractory cell lines, DU 145 and PC3, thus suggesting a potential role in advanced disease after endocrine failure. Combinations of docetaxel with platinum or etoposide may lead to subadditive effects in treatment.